Nurix Therapeutics
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 6 in the most recent period (2026/Q3).
- Total institutional ownership fell 6.8 percentage points.
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 108.91% -6.84pp
- Institutions
- 258 +6
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 17 buys · 33 sells
| Name | Role | Stake |
|---|---|---|
| Arthur Sands | Chief Executive Officer | 0.69% |
| Gwenn Hansen | Chief Scientific Officer | 0.11% |
| Johannes Van Houte | Chief Financial Officer | 0.04% |
| David Lacey | Independent Director | 0.03% |
| Julia Gregory | Independent Chairperson | 0.01% |
| Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | 0.00% |
| Judith Reinsdorf | Independent Director | -- |
| Roy Baynes | Independent Director | -- |
| Lori Kunkel | Former Independent Director | -- |
| Paul Silva | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-03 | Johannes Van Houte | Chief Financial Officer | Automatic Disposition | -4,769 | $15.38–16.20 |
| 2026-11-02 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Automatic Disposition | -10,929 | $25.74–26.76 |
| 2026-11-02 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Intent to Sell (Form 144) | -6,113 | $25.70 |
| 2026-11-01 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Derivative Exercise and Sale | -5,786 | $8.72–25.74 |
| 2026-11-01 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Sale | -1,452 | $1.86–26.80 |
| 2026-10-29 | Johannes Van Houte | Chief Financial Officer | Derivative Exercise and Sale | -2,834 | $26.28 |
| 2026-10-29 | Johannes Van Houte | Chief Financial Officer | Derivative Exercise and Retained | +7,348 | -- |
| 2026-10-29 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Derivative Exercise and Sale | -3,957 | $26.28 |
| 2026-10-29 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Derivative Exercise and Retained | +6,225 | -- |
| 2026-10-29 | Gwenn Hansen | Chief Scientific Officer | Open Market Disposition | -3,957 | $26.28 |
| 2026-10-29 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Retained | +10,182 | -- |
| 2026-10-14 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Sale | -1,452 | $1.86–25.00 |
| 2026-10-13 | Julia Gregory | Independent Chairperson | Derivative Exercise and Sale | -22,583 | $1.86–23.40 |
| 2026-10-01 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Derivative Exercise and Sale | -5,786 | $8.72–23.19 |
| 2026-09-01 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Derivative Exercise and Sale | -5,787 | $8.72–26.64 |
| 2026-08-31 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Sale | -1,452 | $1.86–25.47 |
| 2026-08-04 | Gwenn Hansen | Chief Scientific Officer | Derivative Exercise and Sale | -4,356 | $1.86–25.00 |
| 2026-08-03 | Johannes Van Houte | Chief Financial Officer | Automatic Disposition | -4,761 | $23.89–24.65 |
| 2026-08-03 | Gwenn Hansen | Chief Scientific Officer | Automatic Disposition | -4,111 | $23.87–24.64 |
| 2026-08-02 | Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | Automatic Disposition | -10,802 | $23.05 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Nurix Therapeutics discussion 0 comments